Local family shares experience with familial ALS and efforts to fund research to find a cure
GREENVILLE, Wis. (WFRV) – In a story of resilience and hope, the Weber family stands as a reminder of the impact of familial bonds in the face of adversity.
In 1999, Art Weber passed from amyotrophic lateral sclerosis (ALS), a devastating degenerative disease. A year later, his nine children received news that they carried a genetic strain linked to ALS, with six already diagnosed.
Each family member now faces a daunting 50-50 chance of passing this hereditary condition to their own children.
Beloved Green Bay tattoo studio closes its doors in honor of owner's passing
Jean Micke, a member of the Weber family, expressed the profound unfairness, stating, 'We have five children and nine grandchildren.' Jean herself received an ALS diagnosis in 2020, confronting unimaginable challenges.
Cathy Kettner, president of NextGen ALS and another member of the family, shared her sorrow, recounting the losses of her father and two sisters, Peggy in 2018 and Cindy in 2021.
The oldest sibling, Sharon Sprangers, though symptom-free, has witnessed the toll ALS has taken on her family.
'When Cathy told me she had ALS, it dropped me to my knees,' she recalled. The struggle deepened when her son Sawyer revealed he carries the gene. 'It's not an easy thing,' she added.
Amid the heartache, the Weber family is participating in a promising clinical trial in New York, which aims to halt the progression of ALS. Every three months, they travel to receive spinal injections designed to combat the toxic proteins that attack their muscles.
Sharon shared their hope, stating, 'We found it in our mouse models at Weill Cornell, and now Columbia University is delivering the shots.'
In 2020, out of their shared experiences and determination, the Weber family founded NextGen ALS, a nonprofit dedicated to raising funds for ALS research.
Cathy, diagnosed in 2019, emphasized the organization's mission: 'Sharing and having people understand what ALS is, is vital to our role as an organization.'
Support for the Weber family extends beyond their own ranks. Jim Weber, diagnosed with ALS in 2012, receives vital assistance from the Veterans Affairs (VA), which provides benefits for home renovations and necessary equipment.
His caretaker, Gregory Beyer, who has faced his personal losses from the disease, describes his role as rewarding.
'To take care of Jim, it's 24/7. It's nonstop. It's okay because I love this man; he's a good guy,' Gregory shared, highlighting the joy they find in life despite the challenges.
The Weber family's unity and determination shine through in their fight against ALS. With each passing day, they remain hopeful for a cure to the disease that has taken so much from them.
'I want to say how very proud I am of my sisters and brothers,' Sharon declared, embodying the strength of their bond.
Wisconsin to start new mandatory milk testing to protect public health
NextGen ALS is currently in the middle of a mayhem raffle and preparing for a charity golf event on Saturday, June 21, to further support ALS research.
The four-person scramble will kick off at ten at Mid Vallee Golf Course, with all proceeds directly benefiting the cause. For those looking to make a difference, registration is available online.
Together, the Weber family exemplifies courage, resilience, and an unwavering commitment to fighting ALS, inspiring others to join in their quest for a brighter future.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Tommy Smith – Battling ALS one day at a time
COLUMBUS, Ga (WRBL) – When Tommy Smith was diagnosed with amyotrophic lateral sclerosis back in 2012, his family reacted like any family would. Rallying together around Smith, and that gracious support from his community has benefited Smith in more ways than he can express. ALS robs the body of the ability to walk, talk, eat, work, and in the worst cases the ability to breathe. Relatively, Tommy Smith has been lucky. Where most cases of ALS have a 2-5 year life expectancy, Smith is on year thirteen. For Tommy – ALS has so far robbed him of being a little league umpire, playing with his grandkids without a wheelchair, and speaking normally. That said – it has not been easy. Luckily for Tommy Smith, there's Vickie Smith. The couple met when Tommy was nine years old, and Vickie was seven as next door neighbors. They have been together just short of 46 years. Vickie has been Tommy's caregiver ever since his diagnosis, and has done everything in her power to provide for Tommy. Over the past couple of years, Vickie has had her own health problems. Recently being declared cancer-free, after her second fight with Breast Cancer. Obviously with a disease like ALS, the medical bills pile up quickly. The average cost to care for a person with ALS is $250,000. Major League Baseball has stepped up to the plate in recent years, recognizing those that suffer from the same disease as Hall of Famer Lou Gehrig. Gehrig's name is forever intertwined with the disease, as many refer to it as 'Lou Gehrig's disease'. You can see WRBL's feature of Tommy and Vickie Smith's battle with ALS in the video player above. You can also assist by donating to the Tommy Smith ALS Foundation, on Facebook. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
7 hours ago
- Yahoo
XellSmart Secures FDA Clearance for Three Phase I INDs of Allogeneic iPSC-Derived Cell Therapies Targeting Major CNS Diseases: Parkinson's Diseases, Spinal Cord Injury and ALS
SUZHOU, China, June 2, 2025 /PRNewswire/ -- XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell therapies. To date, the company has received seven Investigational New Drug (IND) approvals for registered clinical trials from both the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA). All approvals focus on clinical-grade, off-the-shelf and allogeneic iPSC-derived cell therapy candidates targeting central nervous system (CNS) diseases with significant unmet medical needs, including: Parkinson's Disease (PD), the world's second most prevalent neurodegenerative disease affecting over 10 million patients globally (Phase I clinical trials in both China and the U.S.); Spinal Cord Injury (SCI), a major CNS disease impacting more than 10 million patients globally (First-in-Class; Phase I clinical trials in China and the U.S.); and Amyotrophic lateral sclerosis (ALS), a devastating rare neurodegenerative disease (First-in-Class; Phase I/II clinical trial in China and Phase I in the U.S.; designated as an Orphan Drug by the U.S. FDA). XellSmart has completed multiple cases of iPSC-derived dopaminergic neural progenitor cell therapy for patients with Parkinson's disease, including"the first case"in China. This clinical study was approved by the National Health Commission (NHC) of China. In the clinical study, clinical-grade iPSC-derived dopaminergic neural progenitor cells were transplanted into the putamen of the striatum in patients with moderate to advanced Parkinson's disease. With follow-up periods exceeding 12 months, no cell therapy-related adverse events have been observed. Multiple patients showed significant improvements in key efficacy indicators, including"on/off"time duration and MDS-UPDRS scores, as well as notable enhancements in non-motor symptoms. XellSmart is committed to developing clinical-grade, off-the-shelf allogeneic iPSC-derived cell therapies targeting central nervous system (CNS) diseases with no effective treatment options. XellSmart is at the forefront of advancing innovative iPSC-based therapies to address major and intractable CNS disorders:In 2023, China's first iPSC-derived cell therapy (XS228 injection), developed by XellSmart, was granted by FDA as Orphan Drug Designation (ODD) for the treatment of amyotrophic lateral sclerosis (ALS). In 2024, China's first national-level registered clinical study of an iPSC-derived cell therapy for Parkinson's disease—also developed by XellSmart—was approved and initiated, including the first case treated in China. In 2024, the world's first national-level registered clinical study of a subtype-specific iPSC-derived neural progenitor cell therapy (XS228 injection) for ALS was approved. Multiple patients, including the world's first ALS case treated with this approach, received therapy with good safety profiles and preliminary data showing slowed disease progression. In 2025, China's first registrational Phase I clinical trial of an off-the-shelf allogeneic iPSC-derived dopaminergic neural progenitor cell therapy (XS411 injection) for Parkinson's disease was launched, led by the National Neurological Disease Medical Center at Beijing Tiantan Hospital. In 2025, China's first randomized, double-blind, controlled Phase I/II clinical trial of XS411 injection was initiated to treat early-onset Parkinson's disease (EOPD), led by Huashan Hospital of Fudan University, a National Neurological Disease Medical Center. In 2025, the world's first registrational Phase I clinical trial of an off-the-shelf, allogeneic iPSC-derived subtype-specific neural progenitor cell therapy was launched by The Third Affiliated Hospital of Sun Yat-sen University, targeting spinal cord injury (SCI) — a major neurological disorder with no effective treatment. In 2025, the world's first Phase I/II registrational clinical trial of XS228 injection—an off-the-shelf, allogeneic iPSC-derived subtype-specific neural progenitor cell therapy—was initiated by Peking University Third Hospital, targeting ALS, a devastating rare neurodegenerative disease. XellSmart has established a fully dedicated, internationally competitive "All-In" team focusing on development of clinical-grade, allogeneic, off-the-shelf iPSC-derived cell therapies for central nervous system (CNS) diseases that currently lack effective treatment options. XellSmart has built a portfolio of proprietary, globally leading industrial technologies and platforms, fueling sustained in-house innovation centered on its core business. To develop iPSC-derived cell therapy candidates, XellSmart has established and operates an R&D center, a B+ and A-grade GMP manufacturing facility, and a quality control center spanning over 5,000 square meters. Multiple clinical-grade iPSC-derived cell therapy candidates developed by XellSmart have completed core CMC development, with fully integrated clinical-grade manufacturing processes and quality control systems in place. XellSmart has successfully produced clinical batches of multiple GMP-grade iPSC-derived subtype-specific neural progenitor cell therapies, currently deployed in multiple clinical trials. XellSmart has secured multiple rounds of financing, collectively led by renowned market-driven venture capital firms including Qiming Venture Partners, Eli Lilly Asia Ventures, Sequoia Capital China (Hongshan), and others. View original content: SOURCE XellSmart Sign in to access your portfolio
Yahoo
7 hours ago
- Yahoo
De Pere selects new Fire Chief to replace retiring Matzke, set to start June 9
DE PERE, Wis. (WFRV) – With the April retirement of Chief Al Matzke, who stepped down from his role after 40 years of service, the De Pere Police and Fire Commission has officially announced the next Fire Chief. Battalion Chief Brett Jansen will become the new chief effective on June 9, officials announced on Monday evening. Appleton's Lamers Dairy brings back 'Cones for a Cause' to raise money during June Dairy Month Jansen, a long-time member with De Pere Fire Rescue, will step into the role after Assistant Fire Chief Jack Mlnrik finishes his time as the interim chief. Chief Jansen has served De Pere for nearly 20 years, starting as a firefighter/paramedic in 2006, until he became a Lieutenant in 2019. His current title of Battalion Chief was earned in 2022. The 2021 Wisconsin State Firefighter of the Year, Jansen, is also the Emergency Medical Services Director, with years of experience. Fire Department Lieutenant in Wisconsin uses chainsaw to create artful park bench Mayor James Boyd released the following statement regarding the selection: 'Battalion Chief Jansen is an exceptional leader, and we're excited to see him step into the role of Fire Chief for our community. The City of De Pere has long taken pride in the strength of its public safety services and overall quality of life. We're confident that Chief Jansen will not only uphold these high standards but also lead the department forward with professionalism, innovation, and a forward-thinking approach to fire and emergency response.' De Pere Mayor James Boyd City Manager Kim Flom added the following statement: 'We are excited to have Brett on board as the next Fire Chief. His commitment to the community and to the continued strength of the organization were evident through the recruitment process.' City Manager Kim Flom No additional details were provided. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
